TherapeuticsMD Inc (NASDAQ:TXMD) CFO Daniel A. Cartwright sold 40,000 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $4.85, for a total transaction of $194,000.00. Following the transaction, the chief financial officer now owns 40,000 shares in the company, valued at $194,000. The sale was disclosed in a filing with the SEC, which is available through this link.

TXMD stock opened at $4.76 on Wednesday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.86 and a beta of 1.40. TherapeuticsMD Inc has a one year low of $4.30 and a one year high of $7.66. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.06. The business had revenue of $3.47 million during the quarter, compared to analyst estimates of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The company’s quarterly revenue was down 21.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.07) earnings per share. Analysts predict that TherapeuticsMD Inc will post -0.62 earnings per share for the current year.

Several research analysts have issued reports on the stock. ValuEngine upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 21st. Oppenheimer set a $14.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, September 26th. Cantor Fitzgerald set a $27.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Thursday, September 27th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, August 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.45.

Several hedge funds have recently added to or reduced their stakes in TXMD. Stevens Capital Management LP purchased a new stake in shares of TherapeuticsMD during the third quarter valued at about $101,000. Managed Account Services Inc. purchased a new stake in shares of TherapeuticsMD during the third quarter valued at about $117,000. Fox Run Management L.L.C. purchased a new stake in shares of TherapeuticsMD during the second quarter valued at about $121,000. Xact Kapitalforvaltning AB lifted its position in shares of TherapeuticsMD by 96.3% during the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after buying an additional 15,600 shares during the last quarter. Finally, Affiance Financial LLC purchased a new stake in shares of TherapeuticsMD during the second quarter valued at about $156,000. 66.24% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD Inc (TXMD) CFO Daniel A. Cartwright Sells 40,000 Shares” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/11/14/therapeuticsmd-inc-txmd-cfo-daniel-a-cartwright-sells-40000-shares.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.